Baxter International (BAX) Bank of America Global Healthcare Conference 2026 summary
Event summary combining transcript, slides, and related documents.
Bank of America Global Healthcare Conference 2026 summary
13 May, 2026Strategic transformation and cultural change
Implemented Baxter GPS (Growth and Performance System) to align all divisions on eight key value creators, including revenue, margin, free cash flow, and ROIC.
Shifted to a decentralized management structure, empowering business units with P&L responsibility to drive change and accountability.
Enhanced bonus and incentive structures to align nearly 100% of staff objectives with business performance, rolled out in Q1.
Leadership emphasizes a high say-do ratio and continuous improvement, with senior staff actively participating in Kaizen events.
Culture change is ongoing, with early progress shown by 231 GPS events in Q1 and increased team engagement.
Portfolio strategy and business focus
Major portfolio shifts, including the kidney care business spin-off, are largely complete, stabilizing the business.
Businesses are categorized into invest and grow, sustain, and fix/divest, with Advanced Surgery highlighted as a growth area.
IV solutions and pharma businesses are positioned for sustaining strong market share and operational efficiency.
Portfolio will continue to evolve, with ongoing customer insight and market analysis guiding future changes.
Financial performance and outlook
Q1 performance exceeded expectations, attributed to improved execution and accountability measures.
Free cash flow improvement is a key focus, with action plans targeting collections, supplier payments, and inventory management.
Margin improvement in the second half of the year is expected from higher volumes, cost structure actions, and cycling through higher-cost inventory.
Full-year guidance was reaffirmed, with proactive management of inflation, supply chain, and cost pressures.
Latest events from Baxter International
- All five proposals, including director elections and governance changes, passed with strong support.BAX
AGM 20265 May 2026 - Q1 2026 sales up 3% reported, adjusted EPS down 35%, full-year outlook reiterated.BAX
Q1 202630 Apr 2026 - Proposal to amend Board size parameters aims to enhance flexibility and governance.BAX
Proxy filing29 Apr 2026 - Q4 sales up 8% but adjusted EPS down 24%; 2026 outlook flat with margin recovery expected.BAX
Q4 202512 Apr 2026 - Shareholders will vote on key governance, compensation, and board structure changes, all recommended for approval.BAX
Proxy filing23 Mar 2026 - Shareholders to vote on director elections, executive pay, auditor, and board size changes.BAX
Proxy filing23 Mar 2026 - Proxy seeks approval for Board refreshment, pay practices, auditor, and sustainability focus.BAX
Proxy Filing13 Mar 2026 - Oil price exposure halved, new operating model boosts efficiency, and margin recovery expected.BAX
Barclays 28th Annual Global Healthcare Conference11 Mar 2026 - Stable fundamentals, prudent 2026 outlook, and focus on innovation and deleveraging.BAX
Citi’s 2026 Unplugged MedTech and Life Sciences Access Day26 Feb 2026